Abstract
Secukinumab is a human immunoglobulin G1/kappa monoclonal antibody targeting interleukin-17A. In clinical trials, 77-81% of the secukinumab patients a......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
